Your right Theravance split up a couple of years ago. The research/drug arm was spun off and kept the Theravance name (TBPH).
Their history was respiratory with their work for GSK. They are now getting around 7% or 8% of the new Treligy COPD drug which is growing nicely. Asthma trials will be reported soon.
They just received approval for a long acting nebulized drug that they partnered with Mylan. That's a 50-50 split.
Going forward they feel that they can target JAK drugs whereas there is little to no systematic involvement. Jansen seems to agree targeting and they are running full speed into ph3 Colitis and ph2/3 in Crohns.
Today they talked about JAK in a number of pre-clinical programs and the IPF program seemed to make sense.
News 
Market Data 
Discover 
